Atropos Health has announced significant advancements in oncology precision medicine with the publication of new artificial intelligence (AI) algorithms aimed at enhancing patient monitoring for paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder. This development, which includes tools for tracking disease progression, is designed to mitigate risks associated with PNH, such as thrombosis, organ dysfunction, and worsening hemolytic anemia.
The newly released AI models complement a previously introduced algorithm intended to improve early diagnosis of PNH. These tools are now available for integration within health systems, allowing clinicians to provide timely interventions for patients already diagnosed with this rare condition.
Dr. Sandeep Jain, Director of Medical Innovation in Hematology & Oncology at Atropos Health, will present findings on the efficacy of these tools at the upcoming ASH Annual Meeting and Exposition in Orlando, Florida. The presentation, titled “Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data,” will take place during the poster session on December 7, 2025, from 18:00 to 20:00 in room OCCC – West Halls B3-B4.
In addition to the AI advancements, Atropos Health has integrated the American Society of Clinical Oncology (ASCO) Guidelines into its platform. This integration aims to provide oncologists and researchers with the latest evidence-based recommendations for patient care. Clinicians using the Atropos platform can now easily access these guidelines, enhancing their ability to deliver personalized treatment options.
Dr. Brigham Hyde, CEO and co-founder of Atropos Health, emphasized the importance of these initiatives, stating, “The future of evidence-based medicine in oncology is being transformed by data and technology. With these two announcements—integration of gold-standard ASCO Guidelines alongside the publication of additional AI models—we are progressing the advancement of precision medicine.” He highlighted that democratizing access to these tools empowers clinicians to navigate complex patient journeys with greater clarity.
This announcement follows the recent launch of the Atropos EvidenceTM Agent, an expert agent designed to generate real-world evidence (RWE). The company is currently embedding personalized evidence within electronic health records (EHR) at Stanford Health Care using data from ChatEHR. In collaboration with Microsoft, Atropos Health is also working to combine ambient encounter data from Dragon Copilot with the Atropos EvidenceTM Agent to further enhance patient care.
Founded on the principle of transforming healthcare through timely and relevant real-world evidence, Atropos Health is known for its innovative approach. The company develops the GENEVA OS®, an operating system designed to streamline access to healthcare evidence across a comprehensive network of real-world data. Healthcare and life science organizations partner with Atropos Health to bridge evidence gaps, improve individual patient outcomes, and expedite research in the field of medicine.
For more information about Atropos Health and its latest innovations, visit their website at www.atroposhealth.com, connect through LinkedIn, or follow on X @AtroposHealth.
